Cosmo Pharmaceuticals N.V.
CMOPFOTCHealthcare● Active
$90.00
$-1.14(-1.25%)
Market Cap$1.5B
P/E Ratio—
52W High$169.9
52W Low$64.37
Cosmo Pharmaceuticals N.V. (CMOPF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CMOPF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.10B | $0.27B | $0.09B | $0.10B | $0.07B |
| Cost of Revenue | $0.06B | $0.02B | $0.04B | $0.02B | $0.02B |
| Gross Profit | $0.05B | $0.25B | $0.05B | $0.08B | $0.05B |
| Gross Margin %(computed) | 46.53% | 92.55% | 57.60% | 81.62% | 76.73% |
| Operating Expenses | |||||
| R&D Expenses | $0.03B | $0.00B | $0.02B | $0.02B | $0.01B |
| G&A Expenses | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Total Operating Expenses | $0.06B | $0.10B | $0.05B | $0.06B | $0.02B |
| Operating Income | ($0.01B) | $0.15B | $0.01B | $0.03B | $0.01B |
| Operating Margin %(computed) | -10.00% | 55.81% | 6.62% | 27.48% | 17.06% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | ($0.00B) | $0.15B | $0.00B | $0.02B | $0.02B |
| Income Tax Expense | $0.00B | $0.02B | $0.01B | $0.01B | $0.00B |
| Net Income | ($0.00B) | $0.13B | ($0.00B) | $0.02B | $0.02B |
| Net Margin %(computed) | -3.46% | 49.94% | -5.32% | 16.87% | 33.30% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.23 | $8.15 | $-0.31 | $1.05 | $1.29 |
| Wtd Avg Shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| EBITDA | $0.00B | $0.17B | $0.02B | $0.05B | $0.02B |
| EBITDA Margin %(computed) | 2.25% | 62.11% | 21.23% | 45.79% | 27.37% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · EUR · B
Explore more Cosmo Pharmaceuticals N.V. data
About Cosmo Pharmaceuticals N.V. (CMOPF) Income Statement
Cosmo Pharmaceuticals N.V. (CMOPF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CMOPF reported revenue of $0.10B, gross profit of $0.05B (gross margin 46.53%), and net income of ($0.00B) — a net profit margin of -3.46%.
Frequently asked questions
CMOPF · 4 questionsCosmo Pharmaceuticals N.V. (CMOPF) reported revenue of $0.10B for 2025, down 60.7% year-over-year.
CMOPF revenueCMOPF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08